Announcements Trials
Browse Landscape

Phase

Phase 2 115Phase 3 34Phase 1/2 22Phase 1 8Phase NA 4Phase 2/3 4Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Breast 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Adenocarcinoma 1Cystadenocarcinoma, Serous 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Paclitaxel 9Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Cisplatin 7Carboplatin 7Radiotherapy, Intensity-Modulated 6Nivolumab 6Leucovorin 6Filgrastim 6Drug Therapy 6Doxorubicin 6Radiotherapy 5Oxaliplatin 5Fluorouracil 5Docetaxel 5Bevacizumab 5gallium 68 PSMA-11 4Taxes 4Sirolimus 4Rituximab 4Melphalan 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Dexamethasone 4Cytarabine 4Capecitabine 4Calcium Dobesilate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × Taxes × Clear all
NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT02065687 2021-09-30

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

GOG Foundation

Phase 2/3 Unknown
469 enrolled 16 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡